论文部分内容阅读
目的观察妥洛特罗贴剂治疗咳嗽变异性哮喘(CVA)患儿的临床疗效和安全性。方法 106例CVA患儿随机分为治疗组和对照组2组。治疗组在吸入性糖皮质激素的基础上给予妥洛特罗贴剂,用法:1~3岁0.5 mg,>3~9岁1.0 mg,>9~12岁2.0 mg,每日1贴。对照组给予盐酸丙卡特罗片剂,用法:6岁以下1.25μg·kg-1·次-1,6岁以上25μg·次-1,2次·d-1。治疗2周后进行咳嗽症状评分,根据咳嗽程度的转变进行疗效判定,观察不良反应,并测定其1秒钟用力呼气容积(FEV1)、最大呼气峰流速(PEF),肺通气功能异常者(FEV1、PEF一项以上<80%)行支气管舒张试验,肺通气功能正常者行运动激发试验。结果 1.治疗组第3天咳嗽症状明显减轻,较对照组止咳见效时间更短(P<0.05);2.治疗2周后,治疗组与对照组总有效率分别为90.4%、79.6%,2组总有效率比较差异有统计学意义(P<0.05);3.治疗组较对照组治疗后FEV1、PEF明显改善(Pa<0.05);4.妥洛特罗贴剂与盐酸丙卡特罗片剂在减轻呼吸道高反应性方面无显著差异(P>0.05);5.妥洛特罗贴剂不良反应发生率低,依从性好。结论妥洛特罗贴剂在儿童CVA治疗中疗效显著,安全可靠,依从性好。
Objective To observe the clinical efficacy and safety of tulobuterol in the treatment of children with cough variant asthma (CVA). Methods 106 cases of CVA were randomly divided into treatment group and control group 2 groups. Treatment group received inhaled glucocorticoid based on the use of tulobuterol patch, usage: 1 to 3 years old 0.5 mg,> 3 to 9 years old 1.0 mg,> 9 to 12 years old 2.0 mg, 1 day. The control group was given Procaterol Hydrochloride tablets. Usage: 1.25μg · kg-1 · 6-year-old, 25μg · -1,2 times · d-1 at 6 years old and below. Cough symptom scores were obtained after 2 weeks of treatment. The curative effect was judged according to the change of cough level. Adverse reactions were observed and forced expiratory volume (FEV1), peak expiratory flow (PEF), and pulmonary dysfunction (FEV1, PEF more than 80%) bronchodilator test, pulmonary ventilation function normal exercise test. After treatment for 2 weeks, the total effective rates of the treatment group and the control group were 90.4% and 79.6%, respectively, and the total effective rates of the treatment group and the control group were 90.4% and 79.6%, respectively The total effective rate in the two groups was significantly different (P <0.05) .3.The FEV1 and PEF were significantly improved in the treatment group compared with the control group (Pa0.05) .ConclusionTocetro- There was no significant difference between the tablets in alleviating the airway hyperresponsiveness (P> 0.05). 5. The incidence of adverse reactions of the tulobuterol patch was low and the compliance was good. Conclusion The use of tulobuterol patch in the treatment of children with CVA significant effect, safe and reliable, good compliance.